The company said that clinical trial data from the U.S. shows that a second dose given two months after the first shot increases protection against moderate to severe COVID-19 to 94%.
Site: https://vocus.cc/article/614a128dfd89780001facc50
A booster shot of Johnson & Johnson’s coronavirus vaccine generates a strong immune response, the company announced on Tuesday.
[ SEE: The Latest News on the Coronavirus Outbreak ]
Recommended Videos
Powered by AnyClip
Explainer: Who is Kremlin critic Alexei Navalny?
Play Video
Explainer: Who is Kremlin critic Alexei Navalny?NOW PLAYING
Microsoft joins GM, Cruise self-driving partnership
Uganda accuses U.S. envoy of trying to subvert election
Spectacular Northern Lights over frozen forest and river
Drone footage shows Swiss vineyards under snow
The company said that clinical trial data from the U.S. shows that a booster shot given two months after the first dose increases protection against moderate to severe coronavirus to 94%. While an extra dose after two months generates a four-fold increase in antibodies, a booster shot given at six months provides a 12-fold increase in antibodies, the company said in a press release.
J&J said it submitted the data, which has not been published in a peer-reviewed journal, to the Food and Drug Administration.
Cartoons on the Coronavirus
View All 561 Images
“It is critical to prioritize protecting as many people as possible against hospitalization and death given the continued spread of COVID-19. A single-shot COVID-19 vaccine that is easy to use, distribute and administer, and that provides strong and long-lasting protection is crucial to vaccinating the global population,” Paul Stoffels, J&J’s chief scientific officer, said in a statement. “At the same time, we now have generated evidence that a booster shot further increases protection against COVID-19 and is expected to extend the duration of protection significantly.”
The announcement comes the week the Biden administration wanted to begin administering booster shots to Pfizer recipients, though the plan faces more regulatory hurdles before extra shots can begin. U.S. health officials said they believed J&J recipients would need a booster shot as well but wanted to wait for additional data.
J&J last month said that interim data from the booster shot trial showed a substantial increase in spike-binding antibodies over the single-shot regimen, though Tuesday’s data shows an even higher jump.
The company said that clinical trial data from the U.S. shows that a second dose given two months after the first shot increases protection against moderate to severe COVID-19 to 94%.
A booster shot of Johnson & Johnson’s coronavirus vaccine generates a strong immune response, the company announced on Tuesday.
[ SEE: The Latest News on the Coronavirus Outbreak ]
Recommended Videos
Powered by AnyClip
Explainer: Who is Kremlin critic Alexei Navalny?
Play Video
Explainer: Who is Kremlin critic Alexei Navalny?NOW PLAYING
Microsoft joins GM, Cruise self-driving partnership
Uganda accuses U.S. envoy of trying to subvert election
Spectacular Northern Lights over frozen forest and river
Drone footage shows Swiss vineyards under snow
The company said that clinical trial data from the U.S. shows that a booster shot given two months after the first dose increases protection against moderate to severe coronavirus to 94%. While an extra dose after two months generates a four-fold increase in antibodies, a booster shot given at six months provides a 12-fold increase in antibodies, the company said in a press release.
J&J said it submitted the data, which has not been published in a peer-reviewed journal, to the Food and Drug Administration.
Cartoons on the Coronavirus
View All 561 Images
“It is critical to prioritize protecting as many people as possible against hospitalization and death given the continued spread of COVID-19. A single-shot COVID-19 vaccine that is easy to use, distribute and administer, and that provides strong and long-lasting protection is crucial to vaccinating the global population,” Paul Stoffels, J&J’s chief scientific officer, said in a statement. “At the same time, we now have generated evidence that a booster shot further increases protection against COVID-19 and is expected to extend the duration of protection significantly.”
The announcement comes the week the Biden administration wanted to begin administering booster shots to Pfizer recipients, though the plan faces more regulatory hurdles before extra shots can begin. U.S. health officials said they believed J&J recipients would need a booster shot as well but wanted to wait for additional data.
J&J last month said that interim data from the booster shot trial showed a substantial increase in spike-binding antibodies over the single-shot regimen, though Tuesday’s data shows an even higher jump.
